JPWO2022271935A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022271935A5
JPWO2022271935A5 JP2023579857A JP2023579857A JPWO2022271935A5 JP WO2022271935 A5 JPWO2022271935 A5 JP WO2022271935A5 JP 2023579857 A JP2023579857 A JP 2023579857A JP 2023579857 A JP2023579857 A JP 2023579857A JP WO2022271935 A5 JPWO2022271935 A5 JP WO2022271935A5
Authority
JP
Japan
Prior art keywords
cancer
egfr
nsclc
kras
crc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525222A (ja
JP2024525222A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034702 external-priority patent/WO2022271935A1/en
Publication of JP2024525222A publication Critical patent/JP2024525222A/ja
Publication of JPWO2022271935A5 publication Critical patent/JPWO2022271935A5/ja
Publication of JP2024525222A5 publication Critical patent/JP2024525222A5/ja
Pending legal-status Critical Current

Links

JP2023579857A 2021-06-24 2022-06-23 Ｅｒｋ１／２阻害剤併用療法 Pending JP2024525222A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214764P 2021-06-24 2021-06-24
US63/214,764 2021-06-24
PCT/US2022/034702 WO2022271935A1 (en) 2021-06-24 2022-06-23 Erk1/2 inhibitor combination therapy

Publications (3)

Publication Number Publication Date
JP2024525222A JP2024525222A (ja) 2024-07-10
JPWO2022271935A5 true JPWO2022271935A5 (https=) 2025-06-24
JP2024525222A5 JP2024525222A5 (https=) 2025-06-24

Family

ID=84544892

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579857A Pending JP2024525222A (ja) 2021-06-24 2022-06-23 Ｅｒｋ１／２阻害剤併用療法

Country Status (8)

Country Link
US (1) US20240316046A1 (https=)
EP (1) EP4358967A4 (https=)
JP (1) JP2024525222A (https=)
KR (1) KR20240055721A (https=)
CN (1) CN117957001A (https=)
AU (1) AU2022300355A1 (https=)
CA (1) CA3223692A1 (https=)
WO (1) WO2022271935A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200071765A1 (en) * 2016-01-19 2020-03-05 The General Hospital Corporation Cancer treatments and methods of selecting same
JP7234418B2 (ja) * 2019-05-16 2023-03-07 イーライ リリー アンド カンパニー Ｂｒａｆｖ６００ｅ大腸癌の治療に使用するためのｅｒｋ１／２阻害剤と、ｂｒａｆ阻害剤およびｅｇｆｒ阻害剤との三重組み合わせ
CA3158910A1 (en) * 2019-10-28 2021-05-06 Asana Biosciences, Llc Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2

Similar Documents

Publication Publication Date Title
JPWO2022271964A5 (https=)
LoConte et al. A multicenter phase 1 study of γ-secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors
Prelaj et al. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program
Lee et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
JPWO2023140329A5 (https=)
Romano et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression
Giommoni et al. Results of the observational prospective RealFLOT study
JP2024023189A5 (https=)
US20240285625A1 (en) Erk1/2 and kras g12c inhibitors combination therapy
Sudhakar et al. The SOS1 inhibitor MRTX0902 blocks KRAS activation and demonstrates antitumor activity in cancers dependent on KRAS nucleotide loading
Hotta et al. Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study
Singh et al. RAS/RAF comutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer
Pu et al. Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
JPWO2022271935A5 (https=)
JPWO2022170060A5 (https=)
McEvoy et al. Investigation of patterns of nodal metastases in BRAF mutant lung cancer
Saiki et al. Characterization of computed tomography imaging of rearranged during transfection-rearranged lung cancer
Riely New targeted therapies for metastatic non–small cell lung cancer
TW202304438A (zh) 使用貝伐拉非尼及考比替尼或使用貝伐拉非尼、考比替尼及阿替利珠單抗的組合療法
Liu et al. Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: a case report
Mori et al. Clinical outcomes of patients with colorectal cancer who underwent comprehensive genomic profiling: a single-institution non-comparative prospective observational study
TW202200147A (zh) Ｂｅｌｖａｒａｆｅｎｉｂ用於癌症治療
JPWO2022109307A5 (https=)
JPWO2022178244A5 (https=)
Patel et al. A rare case of non-small cell lung cancer with BRAF V600E gene: Case report and literature review